|
|
|
|
|
by dmschulman
229 days ago
|
|
The business model for pharma and drug discovery is unfortunately one that requires a lot of upfront investment for research and trials that may or may not pay off as revenue one day. The technology they invented is incredibly promising for new vaccines and they should be attracting enough investment (through contracts or other deals) to continue innovating and saving lives. Maybe they can license it as a last ditch effort to build revenue, but unfortunately the public perceptions about vaccine efficacy is on the wane and government contracts are no longer there to support this vital work both in the present and as a hedge against future pandemics. |
|
- Plan to sink $180-500M+ just in R&D
- Factor in failures, regulatory, clinical, recruitment, phase 1/2 trials and you arrive very quickly around $1.3-2.1 BILLION USD per therapy approved.
...there is a 90% chance that you will spend that $1B+ - and it will fail completely.
https://www.nature.com/articles/d41573-020-00043-x
https://greenfieldchemical.com/2023/08/10/the-staggering-cos...